Gilead Sciences Partners with U.S. State Department and PEPFAR to Accelerate Lenacapavir Approval and Access for HIV Prevention in High-Incidence Countries

Reuters
Sep 05
<a href="https://laohu8.com/S/GILD">Gilead</a> Sciences Partners with U.S. State Department and PEPFAR to Accelerate Lenacapavir Approval and Access for HIV Prevention in High-Incidence Countries

Gilead Sciences Inc. has announced a significant step forward in its mission to combat HIV with the recent positive EU-M4all opinion for lenacapavir, its twice-yearly injectable HIV-1 capsid inhibitor, intended for use as pre-exposure prophylaxis (PrEP). This approval facilitates accelerated regulatory submissions in high-incidence, resource-limited countries, enabling Gilead to pursue swift registrations by the end of 2025 in nations such as Botswana, Kenya, and Vietnam, among others. Gilead has already submitted a filing in South Africa. The company, in partnership with the U.S. State Department and PEPFAR, aims to deliver lenacapavir to up to two million people in countries supported by PEPFAR and the Global Fund over the next three years. This development is part of Gilead's broader access strategy, which includes royalty-free agreements with six generic manufacturers to serve 120 high-incidence countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250903204152) on September 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10